Summary
Anacor Pharmaceuticals Inc (Anacor) is a biopharmaceutical company that discovers, develops and markets small molecule therapeutics based on its boron chemistry platform. The company’s marketed products include a topical solution which is an oxaborole antifungal that is used for the topical treatment of onychomycosis of the toenails. Its lead pipeline candidates encompass a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor for the treatment of mild-to-moderate atopic dermatitis and psoriasis; and an antibiotic for the potential treatment of infections caused from gram-negative bacteria. Anacor’s boron chemistry platform is used to treat diseases in animals caused due to bacteria, fungi and parasites. It out-licensed three investigational compounds: indication targeted at the treatment of an animal health to Eli Lilly and Company; indication for the treatment of human African trypanosomiasis to Drugs for Neglected Diseases; and indication targeted at the treatment of tuberculosis to GlaxoSmithKline LLC. Anacor is headquartered in Palo Alto, California, the US.
Anacor Pharmaceuticals Inc (ANAC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 10
Anacor Pharma Enters Into Research Agreement With Bill & Melinda Gates Foundation 11
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 12
Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 13
iOWH Enters Into Research Agreement With Anacor Pharma 14
Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 15
Equity Offering 16
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 16
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 17
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 18
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 19
Debt Offering 20
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 20
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 22
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 23
Acquisition 25
Pfizer Acquires Anacor Pharma for USD5.2 Billion 25
Anacor Pharmaceuticals Inc - Key Competitors 27
Key Employees 28
Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30
List of Tables
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anacor Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 10
Anacor Pharma Enters Into Research Agreement With Bill & Melinda Gates Foundation 11
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 12
Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 13
iOWH Enters Into Research Agreement With Anacor Pharma 14
Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 15
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 16
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 17
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 18
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 19
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 20
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 22
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 23
Pfizer Acquires Anacor Pharma for USD5.2 Billion 25
Anacor Pharmaceuticals Inc, Key Competitors 27
Anacor Pharmaceuticals Inc, Key Employees 28
List of Figures
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Anacor Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8